0001144204-14-076139.txt : 20141229 0001144204-14-076139.hdr.sgml : 20141225 20141229163450 ACCESSION NUMBER: 0001144204-14-076139 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141219 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20141229 DATE AS OF CHANGE: 20141229 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NORTHWEST BIOTHERAPEUTICS INC CENTRAL INDEX KEY: 0001072379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943306718 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35737 FILM NUMBER: 141313080 BUSINESS ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: (240) 497-9024 MAIL ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 8-K 1 v397649_8-k.htm FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 19, 2014

Northwest Biotherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-35737	94-3306718
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation or organization)	File Number)	Identification No.)

4800 Montgomery Lane, Suite 800

Bethesda, Maryland 20814

(Address of Principal Executive Offices)

(240) 497-9024

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02.

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(e) At the 2014 annual meeting of stockholders of Northwest Biotherapeutics, Inc. (the “Company”), the stockholders approved two matters: the election of two Directors, and ratification of the appointment of Marcum LLP as the Company’s registered independent public accountants for 2014. The stockholders also approved two additional matters on an advisory basis: the Company’s executive compensation arrangements, and the frequency of future stockholder votes, on an advisory basis, on the Company’s executive compensation arrangements.

The Company had recommended that stockholders vote “For” the election of the Directors and the appointment of Marcum. The Company had also recommended that stockholders provide an advisory vote “For” the Company’s executive compensation arrangements, and “For” future shareholder votes, on an advisory basis, on the Company’s compensation arrangements to take place once every three (3) years. The stockholders voted in favor of the Company’s recommendations on all four matters.

Item 5.07.

Submission of Matters to a Vote of Security Holders.

The Company’s 2014 annual meeting of stockholders was held on December 19, 2014. At the meeting, the stockholders voted on two matters: the election of Mr. Bob Farmer and Mr. Jerry Jasinowski as Class II members of the Board of Directors for a three-year term, and ratification of the appointment of Marcum LLP as the Company’s registered independent public accountants for 2014. The stockholders also voted, on an advisory basis, on two additional matters: approval of the Company’s executive compensation arrangements and approval of the frequency of future stockholder votes, on an advisory basis, on the Company’s executive compensation arrangements.

The stockholders voted in favor of the Company’s recommendations on all four matters, as follows.

The stockholders approved the election of Mr. Bob Farmer as a Class II Director for a term expiring at the annual meeting of stockholders in 2017, based upon the following votes:

Member

For

Withheld

Broker Non-Votes

Mr. Bob Farmer

33,299,067

1,556,693

18,021,658

The stockholders approved the election of Mr. Jerry Jasinowski as a Class II Director for a term expiring at the annual meeting of stockholders in 2017, based upon the following votes:

Member

For

Withheld

Broker Non-Votes

Mr. Jerry Jasinowski

33,315,939

1,539,821

18,021,658

The stockholders ratified the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014, based upon the following votes:

For

Against

Abstain

Broker Non-Votes

52,175,637

301,660

400,121

—

The stockholders approved, on an advisory basis, the Company’s executive compensation arrangements based upon the following votes:

For

Against

Abstain

Broker Non-Votes

34,263,783

438,627

153,350

18,021,658

The stockholders approved, on an advisory basis, future stockholder votes, on an advisory basis, on the Company’s executive compensation arrangements once every three years, based upon the following votes:

Every Three Years

Every Two Years

Every Year

Abstain

Broker Non-Votes

30,531,167

242,622

3,836,144

245,827

18,021,658

In accordance with the stockholders’ recommendation, the Company’s Board of Directors has decided to include a stockholder vote, on an advisory basis, on executive compensation in its proxy materials once every three years, with the next such advisory vote occurring in 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NORTHWEST BIOTHERAPEUTICS, INC.


Date: December 29, 2014	By:	/s/ Linda Powers
	Name:	Linda Powers
	Title:	Chief Executive Officer and Chairman